Vivoryon Therapeutics N.V. (FRA:05Y)

Germany flag Germany · Delayed Price · Currency is EUR
1.432
+0.042 (3.02%)
Last updated: Feb 23, 2026, 8:15 AM CET
Market Cap40.63M -21.4%
Revenue (ttm)n/a
Net Income-12.48M
EPS-0.48
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume157
Open1.378
Previous Close1.390
Day's Range1.378 - 1.432
52-Week Range1.346 - 2.020
Betan/a
RSI38.55
Earnings DateApr 24, 2026

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1997
Employees 14
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 05Y
Full Company Profile

Financial Performance

Financial Statements